Position of COMT inhibition in the treatment of Parkinson's disease.
Gordin
Ariel
A
Research Centre, Orion Pharma, Espoo, Finland.
Kaakkola
Seppo
S
Teräväinen
Heikki
H
D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D002394:Catechol O-Methyltransferase / Q000378:metabolism*; D065098:Catechol O-Methyltransferase Inhibitors; D002396:Catechols / Q000009:adverse effects; D004347:Drug Interactions / Q000502:physiology; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000009:adverse effects*; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000378:metabolism*; D009570:Nitriles; D010300:Parkinson Disease / Q000188:drug therapy* / Q000201:enzymology* / Q000503:physiopathology; D018570:Risk Assessment
D065098:Catechol O-Methyltransferase Inhibitors; D002396:Catechols; D004791:Enzyme Inhibitors; D009570:Nitriles; D007980:Levodopa; C071192:entacapone; D002394:Catechol O-Methyltransferase